GCA
AZN icon

Genesee Capital Advisors’s AstraZeneca AZN Stock Holding History

Genesee Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,615
Closed -$661K – 92
2020
Q4 		$661K Sell
6,615
-539
-8% -$57.1K 0.43% 58
2020
Q3 		$784K Buy
7,154
+83
+1% +$9.23K 0.65% 48
2020
Q2 		$747K Buy
+7,071
New +$730K 0.69% 51

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Genesee Capital Advisors's AZN Position: Q1 2021 in Review

Genesee Capital Advisors sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 6,615 shares — an estimated $661K sold.

Genesee Capital Advisors first reported a position in AZN in Q2 2020 and held it in 3 quarters. The position peaked at $784K in Q3 2020. 755 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

  • Genesee Capital Advisors reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
  • Genesee Capital Advisors sold 6,615 AstraZeneca shares in Q1 2021, an estimated $661K.
  • Genesee Capital Advisors first reported a position in AstraZeneca in Q2 2020 and held it in 3 quarters.
  • Genesee Capital Advisors's AstraZeneca position peaked at $784K in Q3 2020.
  • 755 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Genesee Capital Advisors's 13F filing for Q1 2021, filed 16 Apr 2021.